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A B S T R A C T
Cardiac pacemakers are a critical management option for patients with rhythm disorders. Current efforts
to develop leadless pacemakers have two primary goals: to reduce lead-associated post-procedural
morbidity and to avoid the surgical scar associated with placement. After extensive studies on animal
models and technological advancements, these devices are currently under investigation for human use.
Herein, we review the evidence from animal studies and the technological advancements that have
ushered in the era of use in humans. We also discuss different leadless pacemakers currently under
investigation, along with limitations and future developments of this innovative concept.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Contents
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It is estimated that more than 700,000 pacemakers are inserted
annually worldwide [1]. The number of permanent pacemaker
implants is rising due to an increase in mean age of populations* Corresponding author at: University of Pittsburgh School of Medicine, UPMC
Monteﬁore Hospital, 933 West, Pittsburgh, PA 15213, USA. Tel.: +1 412 692 4882;
fax: +1 412 692 4555.
E-mail address: munirb@upmc.edu (M.B. Munir).
http://dx.doi.org/10.1016/j.jjcc.2015.09.006
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsand other medical co-morbidities [2]. Despite the fact that
conventional lead pacemakers improve patients’ clinical status,
the pacing leads have long been considered their Achilles’ heel
[3]. It has been reported that up to 10% of the patients suffer from
acute and chronic lead-associated complications [4]. Similarly,
pacemaker pocket infection continues to be a problem [4] despite
strict adherence to sterile techniques in electrophysiology
laboratories and improved device design. This usually results in
complete removal of entire hardware including battery and leads
and can be a source of signiﬁcant morbidity for the patient. The
incidence of pacemaker lead fracture is about 1–4% [4]. Usuallyreserved.
Fig. 1. St. Jude Medical Nanostim Pacemaker.
Reproduced with permission from St. Jude Medical Services.
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clavicle and ﬁrst rib just lateral to subclavian vein entry site due to
mechanical trauma. Most patients need immediate medical
attention when lead fracture is suspected especially if they are
pacemaker-dependent. Another signiﬁcant issue is lead insulation
failure [4]. Insulation failure can result in abnormal pacing/sensing
and delivery of inappropriate shock therapy all leading to
signiﬁcant short battery longevity. Leadless pacemakers (LCP)
can overcome these issues due to absence of leads and no
requirement for a surgical pocket. Spickler et al. in 1970 were the
ﬁrst to introduce the concept of LCP [5]. The leadless cardiac
pacemaker (LCP) is an innovative concept involving placement of a
completely self-contained intra-cardiac device. Usage of LCPs in
humans became a realistic target when they were successfully
studied in animal models [6]. In this article we review the progress
that has been made in the ﬁeld of LCPs and also analyze the
potential use of LCPs as a ﬁrst choice in various rhythm disorders.
Animal studies and technological advancements
Several studies have been conducted in which the feasibility,
efﬁcacy, and safety of LCPs have been evaluated [6–10]. Spickler
and colleagues were the ﬁrst to successfully implant the LCP in
dogs, but the nuclear-powered device could not be practically used
due to safety concerns and short battery life. In 1991, Vardas et al.
[7] tested their own miniature pacemaker device in 8 dogs. The
pacemaker used was constructed by the research team and
powered by three 1.5 V batteries. The pacemaker did not have any
inherent sensing capability so pacing mode used in the study was
VOO. VOOmode has limited implications in practice and is usually
employed in surgical procedures to avoid sensing of electrical
current generated by electro-cautery. Therefore, this pacemaker
was not deemed suitable for clinical application, even though
pacing was found to be successful in certain dogs [7].
Spickler et al. and Vardas et al.’s research was ahead of its time,
and it was not until 1999 that Goto et al. explored the concept of
using an automatic power-generating system (AGS) to power the
LCP. The AGS converts kinetic energy to electric energy similar to
what is seen in quartz watches. The AGS system is implanted in the
right ventricle, and it transfers kinetic energy to the rest of the
device. It was found that the AGS could generate 13 micro-Joules
per heartbeat, suggesting that it supplied sufﬁcient energy to
power an LCP. The investigators successfully paced amongrel dog’s
heart at 140 beats/min for 60 min with a fully charged AGS system
[11]. Later, in 2006, Echt et al. would go on to use ultrasound as a
power source. Ultrasound energy, which was emitted from a
receiver on the chest wall, would reach an electrode placed in
contact with the myocardium. The electrode would then convert
ultrasound energy to electrical energy and thus cause pacing.
Pacing was achieved in more than 30 different sites in right atrium
and ventricle with ultrasound energy [12]. The same ultrasound
system was used in several other studies and most concluded
ultrasound to be a viable power source. Lee and co-investigators
showed that at 80 different siteswithin the heart, ultrasound could
be used as a power source [13]. They further studied ultrasound
systems and assessed various acoustic windows, which can be
used to deliver ultrasound energy from transmitters on chest wall
to receiver electrodes in the heart [14]. Wieneke et al. brought yet
another power source based on induction using a subcutaneous
transmitter unit and an endocardial receiver unit at the apex of the
right ventricle. Two trials concluded that induction systemswere a
feasible option as a power source and could be used at a distance of
up to 10 cm between the transmitter and receiver units, which is
more than the required 6 cm. This particular source has not been
widely used as of yet, and thus, it remains to be seen if it can be
applied in clinical settings [9,10]. Currently, in most LCPs, thesepower sources are not being used as they need to be further
investigated. LCPs available now are mainly powered by lithium
batteries, and it will continue to be thatway until a better source of
power can be established [15].
Recently, Koruth et al. [8] carried out a study to evaluate the
usage of LCP implanted in the right ventricle of sheep. Pacing was
seen to be successful in 10 out of 11 cases for a period of 90 days.
They concluded that LCP was well suited for use in their sheep
models [8]. Sperzel et al. also used a right ventricle LCP in sheep
models, but their study was focused on retrieval, as well as re-
implantation of the device. It was successfully shown that the LCP
could be easily retrieved and replaced as needed [6]. Although
these studies show acceptable recordings in animals, the efﬁciency
of LCPs in humans had yet to be evaluated.
Current LCPs
Currently, there are three major LCPs being made and tested.
The ﬁrst is the NanostimTM device made by St. Jude Medical (St
Paul, MN, USA). It is smaller than an AAA battery and can be
completely placed within the heart (Fig. 1). Most of the LCP
consists of a battery. This 4-cm long, 6-mm wide, and just 2 g in
weight LCP is delivered by an 18F catheter attached to a docking
button on the end of the device, which introduces it into the body
via the femoral vein and subsequently into the right ventricle. A
tether mode is used to tug on the device after implantation to
ensure that it is ﬁxed to the heart wall. The LCP can be unscrewed
during the operation if positioning needs to be changed or if it has
not been completely ﬁxed. Since it uses electrical impulses to
communicate rather than the standard antenna and coil system it
has a long battery life of 9–10 years, which is particularly useful as
fewer replacements will be needed [15]. After the LEADLESS trial,
this particular LCP was given the CE mark.
Another device is the Micra Transcatheter Pacing System (TPS),
made by Medtronic Inc. (Dublin, Ireland), which is claimed to be
the ‘world’s smallest pacemaker’ with dimensions of just 7 mm in
width, 26 mm long, and weighing 2 g (Fig. 2). Currently, TPS is
undergoing a study in which 780 patients will be enrolled and
followed to evaluate clinical usefulness in terms of major
complications and pacing parameters. Like the NanostimTM device,
the TPS is delivered to the right ventricle via a catheter through
femoral vein, can be repositioned as necessary, and has an
estimated battery life of 7–15 years. Whereas NanostimTM LCP is
ﬁxed mainly by the helix, the TPS is attached by small self-
expanding nitinol tines. The TPS is delivered by a 23F catheter. In
addition, TPS is not intended to be removed when its battery is[(Fig._1)TD$FIG]
[(Fig._2)TD$FIG]
Fig. 2. Micra pacemaker photos. The Micra system is currently investigational in
United States of America.
Photo provided for use by Medtronic International.
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ventricle. This is possible due to the small size of the device. In
younger patients, thismight cause problems down the line due to a
large amount of TPS systems being placed within the ventricle.
Lastly, a Wireless Cardiac Stimulation system (WiCS-LV) is also
being developed by EBR Systems (Sunnyvale, CA, USA). The system
[(Fig._3)TD$FIG]
Fig. 3. Wireless Cardiac Stimulation System (WiCS-LV) technology.
Reproduced with permission from the article ‘‘First-in-man implantation of leadless ultr
resynchronization therapy in heart failure patients’’ by Auricchio et al. [20].utilizes ultrasound emitted from a transmitter implanted subcu-
taneously in the left chest and a receiver implanted in the ventricle
which converts ultrasound energy to electrical energy that can be
used to pace the heart (Fig. 3). In contrast to the aforementioned
devices, the WiCS-LV system has been used in cardiac resynchro-
nization therapy (CRT) when used with conventional right
ventricular pacers. Hence both ventricles will contract almost
simultaneously which allows resynchronization. Another added
advantage of the EBR system (WiCS-LV) is its capability of
endocardial pacing which runs contrary to epicardial pacing seen
with conventional CRT devices. Endocardial pacing may be more
physiological and theoretically could improve patients’ clinical
response to CRT therapy. This hypothesis clearly requires study.
Fig. 4 shows evolution of leadless pacemakers from animal
studies to past and currently ongoing human studies.
Human studies
Recently, Reddy et al. [3] published the ﬁrst study of LCP in
humans using NanostimTM LCP in the landmark LEADLESS trial.
The results showed a successful implantation rate of 97% (n = 32)
with an overall complication-free rate of 94% (n = 31). The authors
concluded that this LCP is feasible for usage andmight prove to be a
pivotal breakthrough in cardiac electrophysiology. Since February
2014, the LEADLESS II trial has started, in which 670 patients are
expected to participate across 50 centers in the USA, Canada, and
Europe [16].asound-based cardiac stimulation pacing system: novel endocardial left ventricular
[(Fig._4)TD$FIG]
Fig. 4. Timeline of leadless pacemaker evolution.
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complications with LCP. In one-year follow-up of 32 out of
33 LEADLESS study patients, 6 perforations were reported, of
which two resulted in death. This led to a halt of the study and was
taken care of with certain measures. Soon after, enrollment for the
LEADLESS II trials was restarted. The electrical performance of the
pacemaker was found to be suitable at 6- and 12-month follow-
ups. Battery longevity was ascertained up until 1 year, but it still
must be evaluated to see if it will last for the expected 8–12 years
[3]. In 61% of cases, the rate response sensor was operational at a
12-month follow-up [17].
Ritter et al. [18] recently published early results from the Micra
Transcatheter Pacing Study. They reported on 140 patients
receiving the TPS in a worldwide prospective study. The mean
follow-up was 1.9  1.8 months. The implant success rate was 100%.
There were no device dislodgements, and TPS sensing and pacing
electrical parameters were stable in follow-up. There were no device-
related serious adverse events resulting in death. One implantation
procedure was complicated by cardiac tamponade. The longer term
safety and efﬁcacy will be evaluated in the ongoing trial, which now
has enrolled approximately 720 patients.
EBR system (WiCS-LV) has also been used in studies by Lee et al.
[13,14,19] and ina studybyAuricchio et al. [20], and is also currently
under investigation in both the WiSE-CRT and SELECT-LV trials.
Auricchio et al.’s study is part of the WiSE-CRT trial and has shown
thatWiCS-LVdevice canbesafely andeffectivelyused forpacingand
that it gives short-to-mid-term symptomatic beneﬁts (Table 1).
Challenges
LCPs are a major advancement in the cardiac pacing world.
Ultimately, LCPs could become the ﬁrst choice for treatment ofTable 1
Comparison of different leadless pacemaker characteristics.
Nanostim wireless pacer Micra transc
Parent company St. Jude Medical Medtronic





Device retrieval Yes Possible a
to put ano
co-existin
Fixation mechanism Screw in helix Self expan
Human studies Yes Yes
Estimated battery life
(company reported)
9–10 years 7–15 yearsymptomatic bradycardia. However this novel techniquewill also
have learning curve-associated problems, which must be kept
into consideration when interpreting data regarding LCP
implants. This is important because there are differences in
implant procedure for each speciﬁc device used, i.e. use of 23F
catheter than 18F, when implanting Medtronic’s device as
opposed to NanostimTM. Also, NanostimTM is ﬁxed to the heart
using screws and Medtronic mainly by tines. Moreover, the
current right ventricular devices are only capable of single
chamber pacing and subsequently do not permit CRT. Hence, only
VVIR pacing is possible [15]. On the other hand, the WiCS-LV
system is capable of CRT. However, WiCS-LV does not have a
deﬁbrillator capability. AAI pacing is not yet possible using these
devices nor can it be used in DDD pacing. Although the promising
technology of leadless pacemakers might minimize the lead-
associated complications, the possibility of new complications
such as device dislodgement, late perforation/tamponade, early
battery depletion, and mechanically induced arrhythmia has yet
to be clinically explored. Early retrieval of LCPs (particularly the
TPS) after the tethering suture has been cut may prove to be
technically challenging. In addition, optimal management of
patients who develop Gram-positive bacteremia late after LCP
implantation (which represents a class I indication for trans-
venous lead extraction) remains unknown. Trans-femoral expla-
nation of the device when dense adhesions form at the interface
with the endocardiummay also prove difﬁcult. On the other hand,
the size of the device and its endothelializationmay allow for less
aggressivemanagement and a higher threshold for LCP extraction
in this setting. Further challenges include cost, physician training,
worldwide accessibility, and long-term follow-up results. Hence,
without the results of long-term trials, it is not possible to make a
ﬁnal decision about LCPs.atheter pacing system Wireless cardiac stimulation system (Wi-CS)
Inc. EBR Systems
CRT when used with conventional
right ventricle (RV) pacer
lver vanadium
on mono-ﬂuoride
Ultrasound transmitter in chest
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In the future, it is hoped that these devices will be used to
manage key cardiovascular disorders especially advanced heart
failure requiring synchrony and bradycardia. After testing safety
and feasibility of LCPs as a whole, the most important develop-
ments needed are increased ease of operation during implant and
replacement, a longer battery life, and long-term working
guarantee. With time it is hoped that LCPs will evolve into a dual
chamber device that allows for resynchronization therapy and can
function as an ICD, which can have both anti-tachycardia pacing
(ATP) and deﬁbrillator capability. Medtronic Micra is already
approved for full body MRI scans [21] and adaptation of other
devices to MRI compatibility may also hasten LCPs’ clinical
acceptance.
Conclusion
LCPs represent a disruptive technology which may revolution-
ize the ﬁeld of cardiac pacing. Apart from possibly reducing
complications associated with surgical pocket and leads, leadless
pacemakers might also improve quality of life. Leadless pace-
makers have been gaining popularity rapidly with results from
multicenter clinical trials expected to be published soon. The LCP
has come a long way since it was ﬁrst conceived. With devoted
efforts from health care industry, we might soon have a new
standard of care for patients requiring pacemaker therapy thus
marking a new era in cardiac pacing.
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